2021
Clinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections
Yi J, Wood JB, Creech CB, Williams D, Jimenez-Truque N, Yildirim I, Sederdahl B, Daugherty M, Hussaini L, Munye M, Tomashek KM, Focht C, Watson N, Anderson EJ, Thomsen I. Clinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections. The Journal Of Pediatrics 2021, 234: 236-244.e2. PMID: 33771580, PMCID: PMC8238832, DOI: 10.1016/j.jpeds.2021.03.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAnti-Bacterial AgentsArthritis, InfectiousChildChild, PreschoolCombined Modality TherapyFemaleGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHumansInfantLogistic ModelsMaleMethicillin-Resistant Staphylococcus aureusOrthopedic ProceduresOsteomyelitisRetrospective StudiesStaphylococcal InfectionsTreatment OutcomeUnited StatesConceptsOsteomyelitis/septic arthritisAcute hematogenous osteomyelitisMethicillin-resistant S aureusSeptic arthritisHematogenous osteomyelitisTreatment failureS aureusOral therapyAntibiotic therapyMusculoskeletal infectionsHigher oddsPediatric musculoskeletal infectionsLonger hospital stayOral antibiotic therapyRetrospective cohort studyTreatment-related complicationsTreatment-associated complicationsHospital stayPediatric infectionsCohort studyParenteral therapyTreatment complicationsIntensive careRecurrent infectionsWorse outcomes
2020
Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosing
2018
Necrotizing fasciitis caused by Mucor indicus in a pediatric bone marrow transplant recipient
Bloch D, Gonzalez MD, Haight A, Abramowsky C, Yildirim I. Necrotizing fasciitis caused by Mucor indicus in a pediatric bone marrow transplant recipient. Pediatric Transplantation 2018, 22: e13294. PMID: 30246483, PMCID: PMC6460914, DOI: 10.1111/petr.13294.Peer-Reviewed Original ResearchConceptsPediatric bone marrow transplant recipientsBone marrow transplant recipientsMarrow transplant recipientsLiposomal amphotericin BSubcutaneous cellular tissueMultiple debridementsTransplant recipientsCase reportRare fungal organismRisk factorsAmphotericin BSusceptibility testingFasciitisFungal organismsAnaerobic bacteria
2010
A Case Report of Thrombocytopenia‐associated Multiple Organ Failure Secondary to Salmonella enterica Serotype Typhi Infection in a Pediatric Patient: Successful Treatment With Plasma Exchange
Yildirim I, Ceyhan M, Bayrakci B, Uysal M, Kuskonmaz B, Ozaltin F. A Case Report of Thrombocytopenia‐associated Multiple Organ Failure Secondary to Salmonella enterica Serotype Typhi Infection in a Pediatric Patient: Successful Treatment With Plasma Exchange. Therapeutic Apheresis And Dialysis 2010, 14: 226-229. PMID: 20438547, DOI: 10.1111/j.1744-9987.2009.00714.x.Peer-Reviewed Original ResearchConceptsSalmonella enterica serotype Typhi infectionMultiple organ failureS. typhi infectionTyphi infectionOrgan failurePlasma exchangeAggressive antimicrobial therapyPlasma exchange therapyLife-saving interventionsConventional supportive measuresSevere sepsisExchange therapyPediatric patientsCase reportAntimicrobial therapySuccessful treatmentSupportive measuresMortality rateAntimicrobial treatmentPatientsThrombocytopeniaInfectionTherapyHigher proportionTreatmentRisks and outcome of fungal infection in neutropenic children with hematologic diseases.
Aytaç S, Yildirim I, Ceyhan M, Cetin M, Tuncer M, Kara A, Cengiz AB, Seçmeer G, Yetgin S. Risks and outcome of fungal infection in neutropenic children with hematologic diseases. The Turkish Journal Of Pediatrics 2010, 52: 121-5. PMID: 20560245.Peer-Reviewed Original ResearchConceptsFebrile neutropenic episodesAcute myeloid leukemiaNeutropenic episodesAcute lymphoblastic leukemiaAplastic anemiaAntifungal treatmentFungal infectionsMortality rateAmphotericin BNeutropenic childrenRetrospective studyLymphoblastic leukemiaMyeloid leukemiaHematologic diseasesTreatment groupsPatientsWhole groupInfectionEpisodesLeukemiaMortalityAnemiaGroupDiseaseFluconazole